Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.39 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.31 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.31 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12483735 | 1.00 | USP2 (0.39) | USP2TSHRALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL8788527 | 1.00 | USP2 (0.39) | USP2TSHRALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL491971 | 1.00 | USP2 (0.39) | USP2TSHRALDH1A1LMNACYP1A2 | |
| SCHEMBL17288070 | 0.97 | TSHR (0.41) | USP2TSHRALDH1A1LMNACYP1A2 | |
| SCHEMBL56742 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3198552 | 0.97 | — | — | |
| SCHEMBL3043105 | 0.97 | TSHR (0.41) | USP2TSHRALDH1A1LMNACYP1A2 | |
| SCHEMBL30087352 | 0.97 | TSHR (0.41) | USP2TSHRALDH1A1LMNACYP1A2 | |
| SCHEMBL491716 | 0.97 | TSHR (0.41) | USP2TSHRALDH1A1LMNACYP1A2 | |
| SCHEMBL944236 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332138-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | VIVOZON, INC. (KR) | 2025-10-30 | — | — | US | disclosed |
| WO-2025120611-A1 | ANTIPARASITIC COMPOUNDS | ANIMOL DISCOVERY, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-3713931-B1 | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | DEUTSCHES KREBSFORSCH (DE) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024246713-A1 | A PROCESS FOR THE PREPARATION OF CDK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | FRESENIUS KABI ONCOLOGY LTD (IN) | 2024-12-05 | — | — | WO | disclosed |
| EP-4470534-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | Vivozon, Inc. (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| WO-2024150597-A1 | THERMOSETTING RESIN COMPOSITION, CURED FILM, SUBSTRATE, AND ELECTRONIC COMPONENT | JNC株式会社 | 2024-07-18 | — | — | WO | disclosed |
| US-20230339976-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
| WO-2023146291-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | 주식회사 비보존 | 2023-08-03 | — | — | WO | disclosed |
| US-5002935-A | Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug | UNIVERSITY OF FLORIDA (US) | 1991-03-26 | — | — | US | disclosed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | disclosed |
| US-4942168-A | INTERMEDIATES FOR 1,2-DIHYDRO-3-METHYL-3H-1,4-OXAZINO 2,3-C!QU INOLINE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | disclosed |
| EP-0327766-A2 | Redox systems for brain-targeted drug delivery | UNIVERSITY OF FLORIDA (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0299345-A2 | Dihydro-1,4-oxazino(2,3-c)quinolines, a process and intermediates for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4743601-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0057700-A4 | Nitrosourea derivatives having antitumour activity and pharmaceutical compositions containing the same. | NAT FOUNDATION FOR CANCER RES (US) | 1982-11-17 | — | — | EP | disclosed |
| EP-0057700-A1 | Nitrosourea derivatives having antitumour activity and pharmaceutical compositions containing the same | NATIONAL FOUNDATION FOR CANCER RESEARCH, INC. (US) | 1982-08-18 | — | — | EP | disclosed |
| WO-1982000642-A1 | NITROSOUREA DERIVATIVES HAVING ANTITUMOR ACTIVITY | WELEBIR A | 1982-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | CACNA2D1 1533/4885SLC6A3 4396/4885SLC6A4 4629/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | CACNA2D1 1609/4885SLC6A3 4484/4885SLC6A4 4651/4885 |
| US-20250332138-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | GRM5, HTR5A, HTR2A | CACNA2D1 4065/4885SLC6A3 75/4885SLC6A4 56/4885 |
| US-20230339976-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CACNA2D1 1530/4885SLC6A3 4528/4885SLC6A4 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.